H. Sarmed, K., K. Dawser, I., H. Sajida, I., I. Khalid, H., A. Saad, H. (2006). Effects of non-steroidal antiinflammatory drugs on the glycemic satae and inflammatory marker in poorly controlled type ii dm patients. , 3(1), 46-51.
Kathem H. Sarmed; Ismail K. Dawser; Ismail H. Sajida; Hussain I. Khalid; Hussain A. Saad. "Effects of non-steroidal antiinflammatory drugs on the glycemic satae and inflammatory marker in poorly controlled type ii dm patients". , 3, 1, 2006, 46-51.
H. Sarmed, K., K. Dawser, I., H. Sajida, I., I. Khalid, H., A. Saad, H. (2006). 'Effects of non-steroidal antiinflammatory drugs on the glycemic satae and inflammatory marker in poorly controlled type ii dm patients', , 3(1), pp. 46-51.
H. Sarmed, K., K. Dawser, I., H. Sajida, I., I. Khalid, H., A. Saad, H. Effects of non-steroidal antiinflammatory drugs on the glycemic satae and inflammatory marker in poorly controlled type ii dm patients. , 2006; 3(1): 46-51.

Effects of non-steroidal antiinflammatory drugs on the glycemic satae and inflammatory marker in poorly controlled type ii dm patients

Al-Mustansiriyah Journal for Pharmaceutical Sciences
Article 1, Volume 3, Issue 1, 2006, Pages 46-51
Authors
Kathem H. Sarmed; Ismail K. Dawser; Ismail H. Sajida; Hussain I. Khalid; Hussain A. Saad
Abstract
Recent studies have shown that inflammatory markers like C-reactive protein (CRP) predicts future
risk of diabetes mellitus (DM), and the data about the relationship between inflammation and the role
of cyclooxygenase (COX) enzyme with type 2 DM are scar. In the present study, the clinical use of
COX-inhibitors to improve glycemic state in type 2, poorly controlled DM patients was tested. Thirty
eight(38) type 2 diabetic patients (12 males and 26 females) with age range of 55±S.E.1.25yrs., who
are maintained on hypoglycemic agents for 6.5±S.E.0.92 years, but with poor glycemic control, were
included in the study and randomly allocated into 3 groups; first group was treated with 25mg/day
rofecoxib and the second was treated with 100 mg/day diclofenac for 2 months. The third group
served as control for comparison. Fasting serum glucose (FSG), glycated hemoglobin (HbA1c), CRP
and body mass index (BMI) were evaluated pre- and post-treatment. All the poorly controlled type
2DM patients included in the study were presented with high CRP levels. Treatment with rofecoxib
and diclofenac for 60 days, showed relatively non-significant decrease in CRP, and did not produce
any significant improvement in glycemic control. It could be concluded that COX pathway may not be
the major contributor to the inflammatory events associated with DM and its associated complications.
Further extensive pharmacologically based evaluation in this respect was necessary.
Statistics
Article View: 113
PDF Download: 55


Journal Management System. Powered by iJournalPro.com